This Phase 1 study, sponsored by Seattle Children's Hospital, focuses on the use of autologous T cells genetically modified to express CD171-specific CARs for the treatment of recurrent/refractory neuroblastoma. Given the high unmet medical need in pediatric oncology, particularly for high-risk neuroblastoma, this asset has significant commercial potential. The market for CAR T-cell therapies is rapidly expanding, with increasing interest from major biopharmaceutical companies. The competitive landscape includes established CAR T therapies and emerging candidates targeting similar indications. Diligence should focus on the safety profile, potential for dose-limiting toxicities, and the scalability of the manufacturing process for CAR T cells, as these factors will influence market entry and adoption.